KIT and acute myeloid leukemia: Similar to the HSCs, CD34+ and CD117+ myeloblasts from AML M4/M5 expressed lower levels of SSEA-3 than their counterparts in NBM (SSEA-3 MMI in CD34+ myeloblasts: 14.1 ± 0.8 vs. 18.5 ± 3.3, p = 0.0735; SSEA-3 MMI in CD117+ myeloblasts: 16.3 ± 1.9 vs. 22.7 ± 4.5 MMI, p = 0.0176) as well as increased levels of SSEA-1 (SSEA-1 MMI in CD34+ myeloblasts: 15.8 ± 4.3 vs. 13.0 ± 1.1, p = 0.2895; SSEA-1 MMI in CD117+ myeloblasts: 35.9 ± 7.7 vs. 17.8 ± 0.8, p = 0.0638).